These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36870236)

  • 1. Letter to the Editor regarding "COVID-19 outcomes in patients with dermatomyositis: A registry-based cohort analysis".
    Lin WJ; Shih PC; Wei JC
    Semin Arthritis Rheum; 2023 Jun; 60():152181. PubMed ID: 36870236
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to "Letter to the Editor Regarding 'COVID-19 outcomes in patients with Dermatomyositis: A registry-based cohort analysis'".
    Pakhchanian H; Raiker R; Agarwal V; Gupta L
    Semin Arthritis Rheum; 2023 Jun; 60():152180. PubMed ID: 36898245
    [No Abstract]   [Full Text] [Related]  

  • 3. COVID-19 outcomes in patients with Dermatomyositis: A registry-based cohort analysis.
    Pakhchanian H; Khan H; Raiker R; Ahmed S; Kavadichanda C; Abbasi M; Kardeş S; Agarwal V; Aggarwal R; Gupta L
    Semin Arthritis Rheum; 2022 Oct; 56():152034. PubMed ID: 35750526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccination outcomes among patients with dermatomyositis: a multicentered analysis.
    Pakhchanian H; Saud A; Raiker R; Kardes S; Aggarwal R; Gupta L
    Clin Rheumatol; 2022 Jul; 41(7):2257-2260. PubMed ID: 35084602
    [No Abstract]   [Full Text] [Related]  

  • 5. COVID-19 as potential aggravating factor for the natural course of new onset-dermatomyositis.
    Faria MSMS; Shinjo SK
    Reumatismo; 2022 May; 74(1):. PubMed ID: 35506321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appearance of anti-MDA5 antibody-positive dermatomyositis after COVID-19 vaccination.
    Sugimoto T; Yorishima A; Oka N; Masuda S; Nakamoto N; Kidoguchi G; Watanabe H; Yoshida Y; Mokuda S; Hirata S
    Mod Rheumatol Case Rep; 2023 Jan; 7(1):108-112. PubMed ID: 35950798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark.
    Chow WH; Gridley G; Mellemkjaer L; McLaughlin JK; Olsen JH; Fraumeni JF
    Cancer Causes Control; 1995 Jan; 6(1):9-13. PubMed ID: 7718740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19-associated myositis may be dermatomyositis.
    Tanboon J; Nishino I
    Muscle Nerve; 2021 Jan; 63(1):E9-E10. PubMed ID: 33095493
    [No Abstract]   [Full Text] [Related]  

  • 9. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr.
    McCann LJ; Juggins AD; Maillard SM; Wedderburn LR; Davidson JE; Murray KJ; Pilkington CA;
    Rheumatology (Oxford); 2006 Oct; 45(10):1255-60. PubMed ID: 16567354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex differential association of dermatomyositis with Sjögren syndrome.
    Tseng CC; Chang SJ; Tsai WC; Ou TT; Wu CC; Sung WY; Hsieh MC; Yen JH
    CMAJ; 2017 Feb; 189(5):E187-E193. PubMed ID: 28246264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study.
    Sigurgeirsson B; Lindelöf B; Edhag O; Allander E
    N Engl J Med; 1992 Feb; 326(6):363-7. PubMed ID: 1729618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study.
    Hill CL; Zhang Y; Sigurgeirsson B; Pukkala E; Mellemkjaer L; Airio A; Evans SR; Felson DT
    Lancet; 2001 Jan; 357(9250):96-100. PubMed ID: 11197446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis.
    Orandi AB; Dharnidharka VR; Al-Hammadi N; Baszis KW;
    Pediatr Rheumatol Online J; 2018 Dec; 16(1):84. PubMed ID: 30594206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Juvenile Dermatomyositis During the SARS-CoV-2 Pandemic: Acral and Oral Mucosal Involvement.
    Giacaman A; Mir Perelló MC; Rodríguez Diez L; Martín-Santiago A
    Actas Dermosifiliogr; 2023 Feb; 114(2):167-170. PubMed ID: 35659614
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-NXP2 antibody-positive dermatomyositis developed after COVID-19 manifesting as type I interferonopathy.
    Okada Y; Izumi R; Hosaka T; Watanabe S; Shijo T; Hatchome N; Konishi R; Ichimura Y; Okiyama N; Suzuki N; Misu T; Aoki M
    Rheumatology (Oxford); 2022 Apr; 61(4):e90-e92. PubMed ID: 34850853
    [No Abstract]   [Full Text] [Related]  

  • 16. COVID-19 or clinical amyopathic dermatomyositis associated rapidly progressive interstitial lung disease? A case report.
    Cao M; Zhang S; Chu D; Xiao M; Liu X; Yu L; Li J; Huang Y; Fang F
    BMC Pulm Med; 2020 Nov; 20(1):304. PubMed ID: 33213393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
    Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter: Pulmonary fibrosis and dermatomyositis.
    Webb DR
    JAMA; 1975 Dec; 234(10):1018-9. PubMed ID: 1242403
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to: 'Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5 positive dermatomyositis associated rapidly progressive interstitial lung diseases: a challenge for the future' by Wang
    Lamb JA; Megremis S; Chinoy H
    Ann Rheum Dis; 2022 Oct; 81(10):e193. PubMed ID: 32759262
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.